Free Trial
LON:APTA

Aptamer Group Final Earnings Report

Aptamer Group logo
GBX 0.34 0.00 (0.00%)
As of 10/2/2026 12:31 PM Eastern

Aptamer Group EPS Results

Actual EPS
GBX 0.71
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aptamer Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aptamer Group Announcement Details

Quarter
Final
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Aptamer Group Earnings Headlines

Aptamer Group (LON:APTA) Sets New 1-Year Low - Here's What Happened
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
Aptamer Group Regulatory News
Aptamer Group PLC
See More Aptamer Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptamer Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptamer Group and other key companies, straight to your email.

About Aptamer Group

Aptamer Group (LON:APTA) is a leading provider of aptamer selection services and developer of aptamer-based reagents for use in research, bioprocessing, diagnostic, and therapeutic applications. Headquartered in York, UK, the Company partners globally to deliver aptamer-based solutions that drive discovery and development across the life sciences. Aptamer Group has developed the proprietary Optimer® platform technology that drives three distinct businesses: Aptamer Solutions, Aptamer Diagnostics and Aptamer Therapeutics. Through the use of its Optimer platform the Company aims to enable new opportunities, including discovery and development partnerships for improved biologic drugs, and new applications, such as novel assays and targets, to accelerate discovery and improve current standard processes. For more information, visit: https://aptamergroup.com/

View Aptamer Group Profile